IN BRIEF: Avacta Not Involved With Medusa 19's Covid Antibody Test

Mon, 17th Aug 2020 20:07

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - States it is not involved with the development of Medusa 19's Covid-19 antibody test. Issues clarification following information appearing on the Medusa 19 website regarding a SARS-CoV-2 antibody test on Friday, adding that performance figures appearing on Medusa 19' site relate to this antibody test and do not relate to Avacta's rapid SARS-CoV-2 antigen test.

Current stock price: 145.00 pence

Year-to-date change: up more than eight-fold from 17.25p

By Ife Taiwo; ifetaiwo@alliancenews.com

Related Shares

More News

1 May 2024 11:53

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...

30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

23 Apr 2024 14:26

UK earnings, trading statements calendar - next 7 days

22 Apr 2024 17:51

TRADING UPDATES: First Tin updates Tellerhauser estimates

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

21 Mar 2024 13:10

Avacta reaches milestone in AVA6000 dose escalation

(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thur...